# A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial)

> **NCT05488340** · PHASE2 · RECRUITING · sponsor: **Locus Biosciences** · enrollment: 318 (estimated)

## Conditions studied

- Urinary Tract Infections

## Interventions

- **DRUG:** LBP-EC01 0.1 x IV dose
- **DRUG:** LBP-EC01 0.01x IV Dose
- **DRUG:** LBP-EC01 IV Infusion Dose
- **DRUG:** Placebo
- **DRUG:** LBP-EC01
- **DRUG:** TMP/SMX

## Key facts

- **NCT ID:** NCT05488340
- **Lead sponsor:** Locus Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-07-13
- **Primary completion:** 2026-06
- **Final completion:** 2026-12
- **Target enrollment:** 318 (ESTIMATED)
- **Last updated:** 2026-03-20

## Collaborators

- Parexel

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05488340

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05488340, "A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial)". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05488340. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*